Our study demonstrated that anti-GPRC5D CAR T-cell therapy induced encouraging efficacy in the R/R MM populations, especially in those who have failed in anti-BCMA CAR T-cell therapy or progressed after responding to the treatment. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.